Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Pharmacist / Member of National Funder’s Committee for Evaluation of Specialised Medicine & MDx at CZ, shared a post on LinkedIn:
“Very relevant and insightful presentations by Atse Huisman and Bishal Gyawali on off-label use and a review of approvals for single-arm trials, at the ESMO 2026 Policy Session, with Jean-Yves Blay as discussant, who highlighted initiatives like PRIME-ROSE /DRUP-like trials as platforms to provide responsible access.”
You can also read: 25 Posts Not to Miss from ESMO Congress 2026: Day 3
